(17912565), R. J. Z. D., (21563237), J. A. P., (18221765), D. F., (114485), L. M., (21563240), C. A., (21563243), J. R., & (8530788), J. C. (2025). Image 1_An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer.jpeg.
Chicago Style (17th ed.) Citation(17912565), Richard Junior Zapata Dongo, Julio A. Poterico (21563237), Diletta Fontana (18221765), Luca Mologni (114485), Carla Alvarez-Chacon (21563240), Juan Rojas-Armas (21563243), and Jaeson Calla (8530788). Image 1_An in Silico Evaluation of Lorlatinib as a Potential Therapy for Novel Amino Acid Substitutions in the Tyrosine Kinase Domain of the ALK Protein Associated with Cancer.jpeg. 2025.
MLA (9th ed.) Citation(17912565), Richard Junior Zapata Dongo, et al. Image 1_An in Silico Evaluation of Lorlatinib as a Potential Therapy for Novel Amino Acid Substitutions in the Tyrosine Kinase Domain of the ALK Protein Associated with Cancer.jpeg. 2025.